Syntax Research Inc. Takes Position in Zoetis Inc. $ZTS

Syntax Research Inc. acquired a new position in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,918 shares of the company’s stock, valued at approximately $2,171,000. Zoetis makes up about 1.5% of Syntax Research Inc.’s investment portfolio, making the stock its 25th biggest holding.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Nova Wealth Management Inc. bought a new position in Zoetis in the first quarter worth approximately $25,000. 1248 Management LLC bought a new position in Zoetis in the first quarter worth approximately $27,000. Saudi Central Bank bought a new position in Zoetis in the first quarter worth approximately $29,000. Cornerstone Planning Group LLC grew its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares in the last quarter. Finally, ORG Partners LLC grew its stake in Zoetis by 56.8% in the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after purchasing an additional 84 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.3%

Shares of NYSE ZTS opened at $146.46 on Friday. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The stock’s fifty day simple moving average is $149.89 and its two-hundred day simple moving average is $155.26. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $64.91 billion, a PE ratio of 25.21, a price-to-earnings-growth ratio of 2.36 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the business posted $1.56 EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ZTS. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Argus reaffirmed a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and dropped their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.